<DOC>
	<DOC>NCT00895804</DOC>
	<brief_summary>MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications. The role of beta-blockers in the treatment of cardiovascular and adverse effects of MDMA is unknown.</brief_summary>
	<brief_title>Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)</brief_title>
	<detailed_description>We investigated the interactive effects of the beta-blocker pindolol (20 mg) with MDMA (1.6 mg/kg) on heart rate, blood pressure, body temperature, and adverse effects in a double-blind placebo-controlled study in 16 healthy subjects.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
	<mesh_term>Pindolol</mesh_term>
	<criteria>Sufficient understanding of the German language Subjects understand the procedures and the risks associated with the study Participants must be willing to adhere to the protocol and sign the consent form Participants must be willing to refrain from taking illicit psychoactive substances during the study. Participants must be willing to drink only alcoholfree liquids and no xanthinecontaining liquids after midnight of the evening before the study session. Participants must be willing not to drive a traffic vehicle in the evening of the study day. Body mass index: 1825 kg/m2 Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (&gt;140/90 mmHg). Personal or firstgrade history of seizures. Cardiac or neurological disorder. Current or previous psychotic or affective disorder Psychotic or affective disorder in firstdegree relatives Prior illicit drug use (except THCcontaining products) more than 5 times or any time within the previous 2 months. Participation in another clinical trial (currently or within the last 30 days) Use of medications that are contraindicated or otherwise interfere with the effects of the study medications.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>MDMA</keyword>
	<keyword>beta adrenergic</keyword>
	<keyword>Ecstasy</keyword>
</DOC>